| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Tumor Biology |
Departments of Pathology, Josephine Nefkens Institute [P. H. J. R., K. J. V., J. C. A., E. G., H. v. D.], Epidemiology and Biostatistics, [W. C. J. H.], and Surgery [H. W. T.], Erasmus University Rotterdam, Rotterdam, and Department of Molecular Cell Biology, Laboratory for Cytochemistry and Cytometry, Leiden University Medical Center, Leiden, The Netherlands [E. G.]
The incidence of adenocarcinoma in Barrett’s esophagus has been increasing rapidly over the past decades. Neoplastic progression is characterized by three well-defined premalignant stages: metaplasia, low-grade dysplasia, and high-grade dysplasia. A genome-wide overview, based on comparative genomic hybridization, was performed, evaluating 30 Barrett’s adenocarcinomas and 25 adjacent precursors, i.e., 6 metaplasias, 9 low-grade dysplasias, and 10 high-grade dysplasias. The frequency of losses and gains significantly increased in the subsequent stages of malignant transformation. Losses of 5q21-q23, 9p21, 17p12–13.1, 18q21, and Y were revealed in low-grade dysplasias. This was followed by loss of 7q33-q35 and gains of 7p12-p15, 7q21-q22, and 17q21 in high-grade dysplasias along with high-level amplification (HLA) of 7q21 and 17q21. In the invasive cancers, additional losses of 3p14-p21, 4p, 4q, 8p21, 13q14-q31, 14q24.3-q31, 16q21-q22, and 22q as well as gains of 3q25-q27, 8q23–24.1, 12p11.2–12, 15q22-q24, and 20q11.2-q13.1 were distinguished along with HLAs of 8p12-p22 and 20q11.2-q13.1. Approximately one-third of the alterations in the dysplasias were also found in the adjacent adenocarcinomas, illustrating that multiple clonal lineages can be present in Barrett’s esophagus. Novel findings include loss on 7q, gain on 12p, and the observation of several HLAs in high-grade dysplasias. Furthermore, loss of 7q33-q35 was found to represent a significant distinction between low-grade and high-grade dysplasia (P = 0.01), whereas loss of 16q21-q22 and gain of 20q11.2-q13.1 were disclosed to significantly discriminate between high-grade dysplasia and adenocarcinoma (P = 0.02 and P = 0.03, respectively). This inventory of genetic aberrations increases our understanding of malignant transformation in Barrett’s esophagus and might provide useful biomarkers for disease progression.
This article has been cited by other articles:
|
|
 |
|
  T. G. Paulson, C. C. Maley, X. Li, H. Li, C. A. Sanchez, D. L. Chao, R. D. Odze, T. L. Vaughan, P. L. Blount, and B. J. Reid Chromosomal Instability and Copy Number Alterations in Barrett's Esophagus and Esophageal Adenocarcinoma Clin. Cancer Res., May 15, 2009; 15(10): 3305 - 3314. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. M. Rygiel, F. Milano, F. J. ten Kate, A. Schaap, K. K. Wang, M. P. Peppelenbosch, J. J.G.H.M. Bergman, and K. K. Krishnadath Gains and Amplifications of c-myc, EGFR, and 20.q13 Loci in the No Dysplasia-Dysplasia-Adenocarcinoma Sequence of Barrett's Esophagus Cancer Epidemiol. Biomarkers Prev., June 1, 2008; 17(6): 1380 - 1385. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. J. Nancarrow, H. Y. Handoko, B. M. Smithers, D. C. Gotley, P. A. Drew, D. I. Watson, A. D. Clouston, N. K. Hayward, D. C. Whiteman, and for the Australian Cancer Study and the Study of D Genome-Wide Copy Number Analysis in Esophageal Adenocarcinoma Using High-Density Single-Nucleotide Polymorphism Arrays Cancer Res., June 1, 2008; 68(11): 4163 - 4172. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. M. Brankley, K. K. Wang, A. R. Harwood, D. V. Miller, M. S. Legator, L. S. Lutzke, B. R. Kipp, L. E. Morrison, and K. C. Halling The Development of a Fluorescence in Situ Hybridization Assay for the Detection of Dysplasia and Adenocarcinoma in Barrett's Esophagus J. Mol. Diagn., May 1, 2006; 8(2): 260 - 267. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. J. Wongsurawat, J. C. Finley, P. C. Galipeau, C. A. Sanchez, C. C. Maley, X. Li, P. L. Blount, R. D. Odze, P. S. Rabinovitch, and B. J. Reid Genetic Mechanisms of TP53 Loss of Heterozygosity in Barrett's Esophagus: Implications for Biomarker Validation. Cancer Epidemiol. Biomarkers Prev., March 1, 2006; 15(3): 509 - 516. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Barclay, A. W. Li, L. Geldenhuys, M. Baguma-Nibasheka, G. A. Porter, P. J. Veugelers, P. R. Murphy, and A. G. Casson Basic Fibroblast Growth Factor (FGF-2) Overexpression Is a Risk Factor for Esophageal Cancer Recurrence and Reduced Survival, which Is Ameliorated by Coexpression of the FGF-2 Antisense Gene Clin. Cancer Res., November 1, 2005; 11(21): 7683 - 7691. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Granelli, M. Cattaneo, S. Ferrero, L. Bottiglieri, S. Bosari, G. Fichera, and I. Biunno SEL1L and Squamous Cell Carcinoma of the Esophagus Clin. Cancer Res., September 1, 2004; 10(17): 5857 - 5861. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. C. Maley, P. C. Galipeau, X. Li, C. A. Sanchez, T. G. Paulson, and B. J. Reid Selectively Advantageous Mutations and Hitchhikers in Neoplasms: p16 Lesions Are Selected in Barrett's Esophagus Cancer Res., May 15, 2004; 64(10): 3414 - 3427. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G.J.S. Jenkins, K. Harries, S.H. Doak, A. Wilmes, A.P. Griffiths, J.N. Baxter, and J.M. Parry The bile acid deoxycholic acid (DCA) at neutral pH activates NF-{kappa}B and induces IL-8 expression in oesophageal cells in vitro Carcinogenesis, March 1, 2004; 25(3): 317 - 323. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. T. Miller, J. R. Moy, L. Lin, M. Schipper, D. Normolle, D. E. Brenner, M. D. Iannettoni, M. B. Orringer, and D. G. Beer Gene Amplification in Esophageal Adenocarcinomas and Barrett's with High-Grade Dysplasia Clin. Cancer Res., October 15, 2003; 9(13): 4819 - 4825. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S H Doak, G J S Jenkins, E M Parry, F R D'Souza, A P Griffiths, N Toffazal, V Shah, J N Baxter, and J M Parry Chromosome 4 hyperploidy represents an early genetic aberration in premalignant Barrett's oesophagus Gut, May 1, 2003; 52(5): 623 - 628. [Abstract] [Full Text]
|
|
|
|
|
|
L. Lin, C. T. Miller, J. I. Contreras, M. S. Prescott, S. L. Dagenais, R. Wu, J. Yee, M. B. Orringer, D. E. Misek, S. M. Hanash, et al. The Hepatocyte Nuclear Factor 3 {alpha} Gene, HNF3{alpha} (FOXA1), on Chromosome Band 14q13 Is Amplified and Overexpressed in Esophageal and Lung Adenocarcinomas Cancer Res., September 15, 2002; 62(18): 5273 - 5279. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. H. J. Riegman, L. J. Burgart, K. K. Wang, J. C. J. Wink-Godschalk, W. N. M. Dinjens, P. D. Siersema, H. W. Tilanus, and H. van Dekken Allelic Imbalance of 7q32.3-q36.1 during Tumorigenesis in Barrett's Esophagus Cancer Res., March 1, 2002; 62(5): 1531 - 1533. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
